HRS9531 Controls Weight Regain in Obese Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a single-center, double-blinded, randomized, placebo-controlled phase II study to explore the effectiveness, safety and energy balance mechanism of low-frequency continuous subcutaneous injection of HRS9531 to inhibit weight regain in obese non-diabetic and obese diabetic patients
Epistemonikos ID: 2281b4afdf3931efc6b2017fb0476d11fe829d28
First added on: May 15, 2024